To reveal the spectrum of gene mutations in grade II/III gliomas, whole exome sequencing of 52 samples including 4 multi-regional and 10 multi-time points sampling cases and 291 SNP-array were performed.
To reveal the spectrum of gene mutations in grade II/III gliomas, whole exome sequencing of 52 samples including 4 multi-regional and 10 multi-time points sampling cases and 291 SNP-array were performed. Our analysis revealed high degrees of temporal/spatial heterogeneity generated during tumor expansion and relapse.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001001213 | Illumina HiSeq 2000 | 5 | |
EGAD00010000682 | 762 | ||
EGAD00010000684 | 3 | ||
EGAD00010000686 | 5 | ||
EGAD00010000688 | 119 |
Publications | Citations |
---|---|
Clonal evolution of glioblastoma under therapy.
Nat Genet 48: 2016 768-776 |
420 |
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities.
Nat Cancer 2: 2021 141-156 |
146 |
Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.
Cancer Res 81: 2021 4861-4873 |
7 |
Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas.
Cell Rep Med 4: 2023 101082 |
1 |
Differential expression of the circadian clock network correlates with tumour progression in gliomas.
BMC Med Genomics 16: 2023 154 |
3 |